Takeda Pharmaceutical Company Limited 4502.T · Stock Open Takeda Pharmaceutical Company Limited in new tab
Takeda Pharmaceutical Company Limited Analysis (4502.T)
Is Takeda Pharmaceutical Company Limited a good investment? Takeda Pharmaceutical Company Limited (4502.T) is currently trading at 4881.00 JPY. Market analysts have a consensus price target of 6130.20 JPY. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 40.76. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Takeda Pharmaceutical Company Limited is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 140.39.
For income investors, Takeda Pharmaceutical Company Limited pays a dividend yield of 3.99%. With a payout ratio of 167%, the dividend appears to be under pressure.
Investor FAQ
Does Takeda Pharmaceutical Company Limited pay a dividend?
Yes, it pays an annual dividend of 204.00 JPY (3.99% yield).
What asset class is Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited is classified as a Stock. You can compare it against 9 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 119.76.
Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
| Year | Total Dividends |
|---|---|
| ▸2027 |
101.00 JPY
|
| March 30, 2027 | 101.0000 |
| ▸2026 |
201.00 JPY
|
| Sept. 29, 2026 | 101.0000 |
| June 25, 2026 | 100.0000 |
| ▸2025 |
198.00 JPY
|
| Dec. 1, 2025 | 100.0000 |
| June 26, 2025 | 98.0000 |
| ▸2024 |
192.00 JPY
|
| Dec. 2, 2024 | 98.0000 |
| June 27, 2024 | 94.0000 |
| ▸2023 |
184.00 JPY
|
| Dec. 1, 2023 | 94.0000 |
| June 29, 2023 | 90.0000 |
| ▸2022 |
180.00 JPY
|
| Dec. 1, 2022 | 90.0000 |
| June 30, 2022 | 90.0000 |
| ▸2021 |
180.00 JPY
|
| Dec. 1, 2021 | 90.0000 |
| June 30, 2021 | 90.0000 |
| ▸2020 |
180.00 JPY
|
| Dec. 1, 2020 | 90.0000 |
| June 25, 2020 | 90.0000 |
| ▸2019 |
180.00 JPY
|
| Dec. 2, 2019 | 90.0000 |
| June 28, 2019 | 90.0000 |
| ▸2018 |
180.00 JPY
|
| Dec. 3, 2018 | 90.0000 |
| June 29, 2018 | 90.0000 |
| ▸2017 |
180.00 JPY
|
| Dec. 1, 2017 | 90.0000 |
| June 29, 2017 | 90.0000 |
| ▸2016 |
180.00 JPY
|
| Sept. 28, 2016 | 90.0000 |
| March 29, 2016 | 90.0000 |
| ▸2015 |
180.00 JPY
|
| Sept. 28, 2015 | 90.0000 |
| March 27, 2015 | 90.0000 |
| ▸2014 |
180.00 JPY
|
| Sept. 26, 2014 | 90.0000 |
| March 27, 2014 | 90.0000 |
| ▸2013 |
180.00 JPY
|
| Sept. 26, 2013 | 90.0000 |
| March 27, 2013 | 90.0000 |
| ▸2012 |
180.00 JPY
|
| Sept. 26, 2012 | 90.0000 |
| March 28, 2012 | 90.0000 |
| ▸2011 |
180.00 JPY
|
| Sept. 28, 2011 | 90.0000 |
| March 29, 2011 | 90.0000 |
| ▸2010 |
180.00 JPY
|
| Sept. 28, 2010 | 90.0000 |
| March 29, 2010 | 90.0000 |
| ▸2009 |
182.00 JPY
|
| Sept. 25, 2009 | 90.0000 |
| March 26, 2009 | 92.0000 |
| ▸2008 |
172.00 JPY
|
| Sept. 25, 2008 | 88.0000 |
| March 26, 2008 | 84.0000 |
| ▸2007 |
152.00 JPY
|
| Sept. 25, 2007 | 84.0000 |
| March 27, 2007 | 68.0000 |
| ▸2006 |
113.00 JPY
|
| Sept. 26, 2006 | 60.0000 |
| March 28, 2006 | 53.0000 |
| ▸2005 |
97.00 JPY
|
| Sept. 27, 2005 | 53.0000 |
| March 28, 2005 | 44.0000 |
| ▸2004 |
85.00 JPY
|
| Sept. 27, 2004 | 44.0000 |
| March 26, 2004 | 41.0000 |
| ▸2003 |
69.00 JPY
|
| Sept. 25, 2003 | 36.0000 |
| March 26, 2003 | 33.0000 |
| ▸2002 |
62.00 JPY
|
| Sept. 25, 2002 | 32.0000 |
| March 26, 2002 | 30.0000 |
| ▸2001 |
55.00 JPY
|
| Sept. 25, 2001 | 30.0000 |
| March 27, 2001 | 25.0000 |
| ▸2000 |
41.50 JPY
|
| Sept. 26, 2000 | 25.0000 |
| March 28, 2000 | 16.5000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | Mar 30, 2027 | Upcoming | 101.0 JPY |
| Takeda Pharmaceutical Company Limited | Sep 29, 2026 | Upcoming | 101.0 JPY |
| Takeda Pharmaceutical Company Limited | Jun 25, 2026 | Upcoming | 100.0 JPY |
| Takeda Pharmaceutical Company Limited | Dec 01, 2025 | Paid | 100.0 JPY |
Community Discussion